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Pharmacokinetics and Metabolism of
Benzene in Zymbal Gland and Other Key
Target Tissues after Oral Administration in
Rats
by Lawrence K. Low,* J. Ralph Meeks,* Kenneth J. Norris,*
Myron A. Mehiman,* and Carl R. Mackerer*
Solid tumors have been reported in the Zymbal gland, oral and nasal cavities, and mammary gland of
Sprague-Dawley rats following chronic oral administration ofbenzene. The cause forthe specificity ofsuch
lesions remains unclear, but it is possible that tissue-specific metabolism orpharmacokinetics ofbenzene
is responsible. Metabolism andpharmacokinetic studies werecarriedoutin ourlaboratorywith '4C-benzene
at oral doses of0.15 to 500mg/kgto ascertain tissue retention, metabolite profile, andelimination kinetics
intargetandnontargetorgansandinblood. Findings fromthosesstudiesindicate thefollowing: a)theZymbal
gland is notasinkor asite ofaccumulation forbenzene or its metabolites even afterasingle high dose (500
mg/kg) or after repeated oral administration; b) the metabolite profile is quantitatively different in target
tissues (e.g., Zymbal gland, nasal cavity), nontarget tissues andblood; andc)pharmacokinetic studies show
that the elimination ofradioactivity from the Zymbal gland is biphasic.
Introduction
Two-year bioassay studiesby Maltoni etal. (1,2)andby
the National Toxicology Program (NTP)(3)have demon-
stratedthat chronic oral administration ofbenzene in rats
produces solid tumors in a number of organs, including
Zymbal gland, nasal and oral cavities, and mammary
gland. It is generally believed that the toxic effects of
benzene result from the metabolism ofbenzene to elec-
trophilic intermediates capable ofinteracting covalently
with critical macromolecules (4-8). Although the exact
chemical nature ofthe ultimate toxic or carcinogenic spe-
cies remains unknown, several metabolic pathways pro-
posed forbenzene lead to the formation ofreactive inter-
mediates. Ofimportance are those pathways givingrise
to mono- and polyhydroxylated metabolites (e.g., phenol,
hydroquinone, catechol, 1,2,4-benzenetriol), ring-opened
metabolites (e.g., muconaldehyde, muconic acid) and
biphenolic metabolites (e.g., 4,4'-biphenol) (9-15). The me-
tabolism ofbenzene has been extensively studied in the
liverandbone marrow(4,19-21), butlittle effort hasbeen
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directed towardinvestigatingthe metabolism ofbenzene
in othertissues(22,23). Targetorgansusceptibility to the
carcinogenic or toxic effects ofxenobiotics is, however,
thought to be governed by many factors with tissue-
specificmetabolism beingofkeyimportance(24,25); such
metabolism mightlead to theformation andpersistence,
at critical levels, ofgenotoxic metabolites.
The studiesreported inthispaperwere designedto in-
vestigate the metabolism and pharmacokinetics ofben-
zeneinthe Zymbalglandandothersolidtumortargetor-
gans in Sprague-Dawley rats after oral administration.
Results were evaluated to delineate differences in the
metabolite profile, elimination kinetics, and bioaccumu-
lationofbenzeneand/oritsmetabolitesinZymbalgland,
nasal and oral cavities, and mammary gland, which are
considered here to be target tissues, and liver and kid-
ney, which are considered to be nontarget tissues.
Materials and Methods
Materials
[UL-14C]Benzene (80-100 mCi/mmole) was purchased
from Chemsyn Science Laboratories (Lenexa, KS); radi-
ochemicalpurityofthis materialwas determinedby RP-
HPLC analysis(70%oMeOH-300owater,v/v)to begreaterLOWET AL.
than 99%. Benzene was obtained from American Burdick
andJackson (Muskegon, MI)(99.7% pureby GC analysis).
Metabolite standards (phenol, hydroquinone, catechol,
1,2,4-benzenetriol, 2,2'-biphenol, 4,4'-biphenol,
trans,trans-muconic acid, phenyl-p-D-glucuronide) were
purchased from Aldrich Chemical Co. (Milwaukee, WI)
or Sigma Chemical Co. (St. Louis, MO) and were greater
than 99% pure. Phenylsulfate was isolated as a metabo-
lite from the urine of rats treated with '4C-benzene,
characterized by selective enzymatic hydrolysis with sul-
fatase, andpurified by HPLC. Glucuronide conjugates of
hydroquinone, catechol, and 1,2,4-benzenetriol were syn-
thesized enzymatically using uridine diphosphate
["4C]glucuronic acid (UDPGA) (304 mCi/mole, New Eng-
land Nuclear) or unlabeled UDPGA and rat liver micro-
somes (22) andpurified by HPLC. Tetrabutylammonium
dihydrogen phosphate, ascorbic acid, and ammonium ace-
tate were obtained from Aldrich Chemical Co. and olive
oil from Sigma Chemical Co. HPLC grade solvents
(acetonitrile, methanol and tetrahydrofuran) were pur-
chased from J. T. Baker (Phillipsburg, NJ).
Animals
Female Sprague-Dawley [Crl:CD(SD)BR] rats were ob-
tained from Charles River Laboratory (Kingston, NY).
Rooms were maintained at20 to 220C with a relative hu-
midity of40 to 60% and a 12-hr light/dark cycle. Animals
receivedfood(rodent chow, #5002pellets, Ralston Purina,
St. Louis, MO) andtap water(automatic waterfeeder) ad
libitum. At study initiation, rats were 12 to 18 weeks of
age and weighed 225 to 375 g.
Methods
Oral Gavage Studies and Tissue Collection. Sprague-
Dawley rats received single doses by oral gavage of "C-
benzene, at 0.15, 1.5, 15, 150, and 500 mg/kg, in olive oil
(nv 0.8-1.0 mL peranimal). The specific activity ofthe oral
gavage doses was adjusted such that each animal
received 30 to 60 MCi. Generally, groups ofthree animals
were sacrificed at 1, 3, 6, 9, 12, and 24 hr after oral ad-
ministration and blood (cardiac puncture), Zymbal gland,
nasal andoral cavitytissues, mammaryglandtissue, bone
marrow (femur), liver, and kidney were collected. Sam-
ples were frozen immediately after necropsy and stored
at -70°C until analyzed. One experiment was caried out
inwhichthree rats received "'C-benzene for2 weeks(500
mg/kg daily, 5 days a week for 2 weeks) and were
sacrificed on day 14 one hrafterthelastradioactive dose.
The amount ofradioactivity inthe Zymbalgland was de-
termined.
Radioactivity Analyses. Determination of total radi-
oactivity, in target and nontarget tissues, and blood was
carried out bymeasuringthe amount of1'CO2 produced
from combustion ofthe samples or a homogenate ofthe
samples. When homogenization of the sample was per-
formed, one equivalent volume (mL) ofcoldwater or cold
0.1 M ascorbic acid solution was added for each gram of
wet tissue. Combustion was carried out for 3 min on a
Harvey Model OX-300 instrument. Radioactivity meas-
urements were quantitated on a Beckman Model LS9000
liquid scintillation spectrometer using appropriate
quench corrections. Tissue concentrations were calcu-
latedusing specific activities ofthe radiolabeledbenzene
oral doses and are expressed in units of "4C-benzene
equivalents (ng or Mg) per gram or per milliliter.
MetaboliteIsolation andHPLCAnalysis. Isolation of
metabolites from blood and the tissues was carried out
according to the following procedure: samples were
homogenized orminced in cold 100 mM ascorbic acid so-
lution [blood, 0.5 mL per 1 mL; liver, kidney, nasal and
oral cavity tissues, mammary gland, 250-500 mg/ml;
Zymbal gland (pooled), 50 mg/500 ML; bone marrow
(pooled), 100-200 mg/500 ML]. Homogenates were ex-
tracted with two volumes ofethyl acetate to isolate the
unconjugatedmetabolites, andethyl acetate andaqueous
layers were separated by centrifugation. The aqueous
layerwas extracted a second time with ethyl acetate and
the organic fractions combined. Ethyl acetate was re-
moved under a stream of nitrogen gas and the residue
reconstituted in the HPLC mobile phase (5%
acetonitrile-95% 0.1 M ammonium acetate, pH 4.0, v/v);
separation ofthe unconjugated metabolites was carried
outby HPLC usingthe conditions described below. The
remaining aqueous fraction was treated with an
equivolume ofmethanol to precipitate proteins, followed
by centrifugation. The supernatantfraction was isolated
and methanol removed under a stream ofnitrogen gas;
separation ofthe water-soluble, conjugated metabolites
present in this aqueous sample was carried out by ion-
pairHPLC as describedbelow. HPLC analyseswereper-
formed on a Beckman model 330 binary gradient high
performance liquid chromatographic system consisting of
two model 110A pumps, a model 420 controller and a
model 210 injector (Beckman Instruments, Fullerton,
CA) or on a Varian 5020 binary gradient HPLC system
with two single-piston solvent delivery pumps, an inter-
nal microprocessor controller and a Varian 9090 injec-
tor/autosampler (Varian Instruments, Walnut Creek,
CA). Reverse-phase (RP) columns (AltexODS, 4.6mm x
15 cm or 25 cm) with Brownlee C8 (4.6 mm x 30 mm)
guard columnswere usedin most ofthe HPLC analyses.
Identification of radiolabeled benzene metabolites was
based on comparison of retention times of radiolabeled
HPLC peakswith those ofstandards. Detection ofthese
standardmetabolites was carried out by monitoringthe
UV absorbance (254 nm) of the HPLC effluent with a
Beckman model 153fixed wavelength instrument. Radi-
olabeled glucuronide and sulfate standards were moni-
toredwith a Berthold flow-through model LB506C radi-
oactivity detector.
Radiometric-HPLCAnalysis ofMetabolites. Uncon-
jugatedmetabolitespresentinthe evaporated ethyl ace-
tate sample were separated on an Altex ODS HPLC
column(4.6 mm x 15 cm)usingthe chromatographic con-
ditionsreportedby Lunte andKissinger(26); elutionwas
carried out with 5% acetonitrile-95% 0.1 M ammonium
acetate (pH 4.0) (v/v) at a flow rate of 1 mL/min. The
water-soluble metabolites were separated using an ion-
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pair HPLC procedure slightly modified after the one
reported by Sabourin et al. (22). Briefly, an Altex ODS
column (4.6 mm x 25 cm) was initially equilibrated with
10% methanolic tetrabutylammonium dihydrogen phos-
phate(TBAP, 30mM)/ 90% aqueous TBAP(50mM). Fol-
lowing injection, the HPLC column was eluted using a
10-min linear gradient from 10% methanolic TBAP to
45% methanolic TBAP at a flow rate 1 mL/min. At 10
min, the methanolic TBAP solvent was replaced with a
solvent mixture containing 90% methanolic TBAP (30
mM) and 10% tetrahydrofuran (THF)(v/v) and the HPLC
column eluted isocratically with 45% methanolic
TBAP/THF (90:10)/55% aqueous TBAP. The column was
allowed to reequilibriate with 10% methanolic TBAP
/90% aqueous TBAP before another injection was made.
The HPLC effluent was monitored withaBertholdModel
LB506C flow-through radioactivity detector. Alterna-
tively, fractions ofthe eluate (0.5 mL) were collected in
scintillation vials and 15 mL ofcocktail fluid(Ready Sovl
CP, Beckman, Fullerton, CA) added to each vial. Radi-
oactivity in thefractions was determined with a Beckman
model LS9000 liquid scintillation instrument.
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Results
Absorption and Distribution
The time course ofdisposition and elimination ofradi-
oactivity in Zymbalgland and other organs afteroral ad-
ministration of0.15 and 1.5 mg/kg 14C-benzene is shown
in Figures 1 and2. The highestlevels ofradioactivityfor
all tissues and organs were seen at the earliest sampling
period (1 hr), suggesting that peak levels could have oc-
curred somewhatearlier. However, levels differed among
certain tissues and organs over the entire sampling
period. One hour after single oral doses of 0.15 and 1.5
mg/kg 14C-benzene (Table 1), concentrations ofradioac-
tivity fell roughly into three groups: the highest levels
werefound inliver and kidney; the lowestlevels in Zym-
bal gland, nasal cavity tissue, oral cavity tissue, mam-
mary gland, and bone marrow; and intermediate levels
in blood. However, this distribution was altered at 15
mg/kg where disproportionate increases were found in
mammary gland and bone marrow.
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FIGURE 1. 14C concentrations in the Zymbal gland, and various other
target and nontarget organs in Sprague-Dawley rats following a sin-
gle oral dose ofbenzene (0.15 mg/kg). Points represent the means of
three animals.
Time (hr)
FIGURE 2. 14C concentration in the Zymbal gland and various other tar-
get andnontarget organs inSprague-Dawley ratsfollowing asingle
oral dose ofbenzene (1.5mg/kg). Pointsrepresent the means ofthree
animals.
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Table 1. Concentration of radioactivity in various tissues 1 hr fol-
lowing oral administration of0.15, 1.5 and 15 mg/kg '4C-benzene.
ig Benzene equivalents/g or mL, ppma
Tissue 0.15 mg/kg 1.5 mg/kg 15 mg/kg
Zymbal gland 0.034 ± 0.006 0.380 ± 0.059 3.2 ± 0.4
Nasal cavity 0.044 ± 0.008 0.547 ± 0.123 2.4 ± 0.8
Oral cavity 0.035 ± 0.001 0.359 ± 0.017 2.4 ± 0.2
Mammary gland 0.028 ± 0.008 0.373 ± 0.055 6.6 ± 1.4
Blood 0.086 ± 0.004 0.769 ± 0.073 6.3 ± 0.9
Bone marrow 0.058 ± 0.005 0.490 ± 0.077 10.1 ± 1.3
Liver 0.198 ± 0.006 2.043 ± 0.195 12.8 ± 1.4
Kidney 0.254 ± 0.005 1.926 ± 0.174 12.2 ± 1.2
aValues represent mean ± SEM for three animals.
Elimination from Target Tissues
The eliminationofradioactivity inthe Zymbalgland oc-
curred in a biphasic manner (Fig. 3); the 4C elimination
half-life for the rapid phase was 2.4 to 2.8 hr, while the
half-life of the slow phase was 18 to 21 hr (Table 2). As
evident in Figures 1 and 2, elimination of 14C from the
nasal and oral cavities, mammary gland, blood, liver, kid-
ney, and bone marrow also displayed biphasic kinetics.
During the first 8 to 10 hr, elimination ofradioactivity oc-
curredrapidly inthese tissues; butafterthisperiod, radi-
oactivity disappeared at a much slower rate. The half-
lives of 14C elimination (rapid and slow phases) for vari-
ous target and nontarget tissues are summarized in Ta-
ble 2; forthe 0.15mg/kgdose, the tl2 forthe rapidphase
rangedfrom 2.2 hrforblood to4.2 hrforkidneywhile the
t1/2 for slow phase rangedfrom 11 hrforbone marrow to
29 hr for blood. All ofthe radioactivity in blood and tis-
sues 1 hr after the 0.15 mg/kg dose appeared as benzene
metabolites, indicating very efficient first-pass metabo-
lism of benzene by the liver after oral absorption.
Accumulation in Zymbal Gland
The amount ofbenzene-derived material remaining in
the Zymbal gland24 hr aftersingle gavage doses of0.15,
1.5, 15, 150, and 500 mg/kg 14C-benzene constituted less
than 0.0001% ofthe administered dose, indicating that ac-
cumulation of14C does not occurin thisgland. There was
some evidence, based on tissue/blood ratios and extrac-
tion studies, that 14C-benzene might be sequestered in
mammary gland, bone marrow, and adipose tissue when
animals were dosed with radiolabeled benzene at or
above 15mg/kg(Table 1). However, there was no indica-
tion that C was selectively retained by the Zymbal
gland in comparison to mammary gland and adipose tis-
sue. Since it hasbeenreportedthat fatty tissues(e.g., adi-
pose, bone marrow) might function as a depot or sinkfor
benzene (9,27), one experiment was carried out to specif-
ically deternine if14C-benzene residuesaccumulate inthe
Zymbal gland (a sebaceousgland) afterrepeated oral ex-
posure. After 2 weeks of oral dosing at 500 mg/kg (sin-
gle dose daily 5 days perweekfor twoweeks), no appar-
ent accumulation of 14C was observed in the Zymbal
gland compared to that after a single oral dose (data not
shown).
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FIGURE 3. Comparison of 14C levels in the Zymbal gland in rats given
a single oral low dose ofbenzene of0.15, 1.5and 15mg/kg. Points rep-
resent the means ofthree rats. For the 15mg/kg dosegroup, tissues
were not taken at the 12-hr time interval.
Table 2. Half-life ofelimination ofradioactivity from Zymbal gland
and other tissues.a
Rapid phase, Slow phase,
Tissue Dose, mg/kg t1/2, hr tw/2, hr
Zymbal gland 0.15 2.8 18
Zymbal gland 1.5 2.4 21
Zymbal gland 15.0 2.5 8b
Blood 0.15 2.2 29
Blood 1.5 2.1 23
Blood 15.0 2.5 8b
Mammary gland 0.15 2.6 NCC
Nasal cavity 0.15 2.6 17
Oral cavity 0.15 2.9 23
Bone marrow 0.15 3.2 11
Liver 0.15 2.8 21
Kidney 0.15 4.2 14
aHalf-life ofelimination ofradioactivity forthe rapid and slowphases
was estimated by visualizing thebestline graphically on semilogplots
and thenbest-fitting the datapoints for each phase using an exponen-
tial curve-fitting program on an HP 41CX calculator.
bOnly two datapoints were available for determining half-life ofthe
slow phase.
cNot calculable.
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Metabolite Profile
The metabolites in Zymbal gland and other tissues
were obtained byextraction, separated, and measured by
HPLC and liquid scintillation spectrometry. Ethyl ace-
tate extraction was used to isolate the unconjugated
metabolites of benzene (e.g., phenol, hydroquinone,
catechol, biphenol). HPLC separation ofthese free phe-
nolic metabolites was achieved using an acetonitrile-
ammonium acetate mobile phase (26). Separation of
water-soluble metabolites ofbenzene (e.g., glucuronides,
sulfates) was accomplished using an ion-pair HPLC gra-
dient elution method (22). Radiochromatograms, such as
those shown in Figure 4, illustrate the excellent baseline
resolution ofthe water-soluble metabolites using the ion-
pair HPLC procedure. The retention times for various
standard metabolites performed under these two HPLC
schemes are listed in footnote c ofTable 3. The relative
percentages ofunconjugated and water-soluble metabo-
litesfound in Zymbal gland, oral and nasal cavity tissues,
bone marrow, liver, kidney, andblood 1 hrafter oral ad-
ministration of 15 mg/kg "4C-benzene are shown in
Table 3.
Zymbal Gland. The major unconjugated metabolite
identified in the Zymbal gland was hydroquinone(v 30%
ofunconjugated metabolite fraction) but small amounts
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FIGURE 4. HPLC radioactivity profile ofthe water-soluble metabolite fraction isolated from various tissues and from blood 1 hr after female Sprague-
Dawley rats were orally administered 15 mg/kg '4C-benzene in olive oil: (A) Zymbal gland; (B) blood; (C) nasal cavity tissue; (D) kidney. Isolation
procedures and ion-pair HPLC conditions are given in the materials and methods section. See Table 3 for relative percentages of each identified
benzene metabolite and their HPLC retention times.
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Table 3. Relative percentage of benzene metabolites in Zymbal gland and other tissues I hr after a 15 mg/kg '4C-benzene oral dose.a
% Total radioactivity in ethyl acetate or aqueous fractions in tissue
Metabolite Zymbal gland Nasal cavity Oral cavity Bone marrow Mammary gland Blood Liver Kidney
Unconjugated metabolites in
ethyl acetate fractionb
Hydroquinone 30 11 53 _d _d 64 89 65
Catechol NDC ND ND - - ND ND ND
Phenol 3 29 31 - - 2 3 26
Unidentified 67 60 16 - - 34 8 9
(1 major peak) (1 major, 1 (2 peaks) (2 peaks)
minor peak)
Water-soluble metabolites in
aqueous fractionb
Phenyl sulfate ND ND 62 66 _d 83 26 23
Phenyl glucuronide 35 18 3 ND - 2 2 3
Muconic acid ND 6 14 11 - 6 5 15
Hydroquinone glucuronide ND ND 4 2 - 2 8 6
Unidentified and
other metabolites 65 76 18 22 - 6 56 53
(1 major, 2 (major peak, (4 minor (4 minor (2 minor (major peak (2 peaks
minor peaks) 23.5 min, peaks) peaks) peaks) at 5 min, at 3-5 min,
catechol 27%) 31%)
glucuronide, 53%)
aSee "Materials and Methods" for metabolite isolation procedure and HPLC conditions for separation ofmetabolites in the ethyl acetate fraction
and in the aqueous fraction.
bHPLC retention times ofunconjugated metabolites: 1,2,4-triol (3.0 min); hydroquinone (4.5 min); catechol (9.0min); phenol (20min). HPLC retention
times (ion-pair) for water-soluble metabolites: hydroquinone glucuronide (14.0 min); triol glucuronide (major isomer, 16.0 min); muconic acid (17.5
min); phenyl glucuronide (21 min); catechol glucuronide (22.5 min); phenylsulfate (31 min).
CND, not detected.
dEthyl acetate extraction wascarried out on bone marrow homogenate, but evaporation ofsolventyielded4ittle ifany radioactive residue for HPLC
analysis. Radioactivity lost most likely parent material. Similar findings occurred with mammary gland, radioactivity was not found in the evapo-
rated ethyl acetate fraction or aqueous fraction.
ofphenol (r\ 3% ofunconjugated fraction) were detected.
However, about 67% of the radioactivity in the uncon-
jugated fraction was associated with a polar, unknown
peak having a retention time ofless than 3 min. Efforts
are underway to isolate sufficient quantities ofthispolar
productfrompooled Zymbalglandsformass spectromet-
ric identification and structure elucidation. Free biphen-
olic metabolites were not detected in the Zymbal gland.
Phenylglucuronide was identified as a water-soluble
metabolite in the Zymbal gland based on retention time
comparison with standards (Fig. 4A). Phenylsulfate and
muconic acid were not detected as water-soluble metabo-
lites in the Zymbalgland at 1 hr. The absence ofphenyl-
sulfate inthe Zymbalglandwas surprising sincethis sul-
fate conjugate was found as the principal water-soluble
metabolite in blood (Fig. 4B), bone marrow, oral cavity,
urine, and othertissues in ourstudies. About 65% ofthe
radioactivity in the aqueous metabolite fraction of the
Zymbalglandremainedunidentified; mostoftheradioac-
tivity was associated with apolar peak that elutes from
the column at about 5 min (Fig. 4A, Table 3). The un-
known polar peak does not appear to be prephenylmer-
capturic acid or a diconjugate based on relative retention
times reported in the literature (22,28). However, the
chromatographic nature of this polar product might be
consistent with a structure such as a metabolite ofmu-
conic acid(e.g., shorter open-chain acid oralcohol metabo-
lite) or a S-oxide metabolite of a mercapturic acid or
premercapturic acid. Further characterization studies
need to be carried out to evaluate these possibilities.
Blood. The unconjugated metabolites found in blood
were hydroquinone and phenol, along with two uniden-
tified polar products (Table 3). The HPLC profile ofthe
water-soluble metabolites in blood 1 hr following a 15
mg/kg oral dose of "4C-benzene is shown in Figure 4B.
The major metabolite (31 min) coeluted with phenylsul-
fate and comprised 83% ofthe radioactivity in the aque-
ous fraction. In addition, muconic acid, phenyl-
glucuronide, andhydroquinoneglucuronide were detected
as minor metabolites (2 to 6%) in blood (Table 3).
Nasal Cavity Tissue. Unconjugated metabolites iden-
tified in the nasal cavity tissue included phenol (29% of
unconjugatedfraction) and hydroquinone (11%), while the
majorunknownmetabolite (rv 60%) eluted as apolarpeak
on HPLC. The spectrum of water-soluble metabolites
found in the nasal cavity tissue was different from that
found inblood and othertissues in thatphenylsulfate was
notdetected inthe nasal cavity. Phenylglucuronide (18%)
and muconic acid (6%) were identified as water-soluble
metabolites in nasal cavitytissues, but amajority ofthe
radioactivity in the aqueous fraction (76%) remained
unidentified (Fig. 4C). Themajorradioactive HPLCpeak
eluted at 23.5 min and represented 53% of the aqueous
fraction isolated from nasal cavity tissue.
OtherTissues. Themetaboliteprofiles invarious other
tissues including bone marrow, oral cavity tissue, mam-
marygland, liver, andkidneyhave alsobeen determined
and are summarized in Table 3. The radioactivity found
in the bone marrow 1 hr after a 15 mg/kg oral benzene
dose was mainly parent and water-soluble metabolites
(Table 3). Phenylsulfate, muconic acid, and hydro-
quinoneglucuronide were identified as the major water-
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soluble metabolites in the bonemarrow. In oral cavitytis-
sue, hydroquinone and phenol were the principal uncon-
jugated metabolites, while phenylsulfate, muconic acid,
phenylglucuronide and hydroquinoneglucuronide were
the primary water-soluble metabolites. Based on extrac-
tion results, the 14C material present in mammary gland
appeared to be the parentmaterial. Afterattemptediso-
lation of metabolites, practically no radioactivity was
found in the aqueous fraction orthe evaporatedethyl ace-
tate fraction, indicating that the radioactivity initially as-
sociated with the ethyl acetate fraction was lost as "C-
benzene during evaporation of ethyl acetate. Uncon-
jugated metabolites detected in the kidney were hydro-
quinone andphenol. Phenylsulfate (23%)andmuconic acid
(15%) were the major water-soluble products while the
glucuronide conjugates ofphenol andhydroquinone were
minor water-soluble metabolites (3 to 6%). The metabo-
liteprofile inthe liverappears tobe similarto thatfound
inthe kidneyexceptthat the relative percentages ofmu-
conic acid and unconjugated phenol were lower in the
liver than in the kidney. A substantial portion of the
water-soluble metabolites in Zymbalgland, liver, kidney,
and nasal cavity tissue remained poorly characterized
(Table 3); most of these products were polar in nature.
Discussion
Although solid tumorformation occurs in a number of
tissues in rats following chronic oral benzene exposure
(1-3), information has notbeenreported onthe metabolic
disposition andpharmacokinetics ofbenzene atthese tar-
gets sites, which include Zymbal gland, oral and nasal
cavitytissues, andmammarygland. Ofparticularinterest
is the Zymbalgland since this tissue is most susceptible
to neoplastic changes induced by benzene. In this pres-
entstudy, we report the pharmacokinetics and metabo-
lism of 1 C-benzene in Zymbal gland and other solid tu-
mor target tissues in the Sprague-Dawley rat. Our
results indicate that after oral administration, radiola-
beled benzene is rapidly absorbed and distributed to the
Zymbalgland, withpeaklevelsreachedwithin 1 hrofad-
ministration. Subsequent elimination ofradioactivity oc-
curs in a biphasic manner (rapid and slow phases). The
slower eliminationphase suggests areduced rate ofclear-
ance ofmetabolites from the Zymbal gland, possibly be-
cause ofcovalentbinding to tissue proteins. HPLC radi-
ometric analysis demonstrated the presence ofbenzene
metabolites in the Zymbal gland after treatment with
"C-benzene. Free hydroquinone and phenol were de-
tected as unconjugated metabolites, and phenyl-
glucuronide as a water-soluble metabolite, on the basis
of HPLC retention times. Other metabolites in Zymbal
gland were polarin nature and have not been identified.
The metabolite profile found in the Zymbal gland
differs from those found in blood and other tissues and
is characterized by the absence of phenylsulfate. This
finding is surprising since phenylsulfate is the predomi-
nant water-soluble metabolite of blood, liver, kidney,
bone marrow, oral cavitytissue, andurine. These results
are consistent with previous findings that sulfate conju-
gationmay not occurreadilyinthe Zymbalgland; Irving
et al. (29) have reported that Zymbal gland lacks sul-
fotransferase activity toward N-hydroxy-2-acetylamino-
fluorene in the rat. Therefore, detoxification ofphenolic
xenobiotics in the Zymbalgland maybe mainly proceed-
ing by glucuronidation or possibly by other conjugative
or metabolic pathways leading to polar products. The
presence of phenylglucuronide and an unknown polar
product as majorwater-soluble metabolites in the Zym-
balglandofanimalstreatedwithbenzene appearsto sup-
port this hypothesis. The significant difference between
the metabolite profile inbloodversus that inthe Zymbal
gland suggests inherent metabolic capability in the Zym-
bal gland to biotransformbenzene and/oritsmetabolites.
If metabolites in the blood were transported to and se-
questered bythe Zymbalglandratherthanbeingformed
there, one would expect the two metabolicprofiles to be
more similar than distinctly different as experimentally
observed. Pohl and Fouts (30) have demonstrated that
Zymbal gland homogenates possess cytochrome
P-450-dependent xenobiotic-metabolizing activity toward
benzo[a]pyrene and 7-ethoxycoumarin. Studies in our lab-
oratory using an in vitro tissue culture technique have
demonstrated that the Zymbal gland is capable of
metabolizing benzene, 2-acetylaminofluorene, and
7,12-dimethylbenzanthracene to reactive intermediates
that interact covalently with DNA (31).
At this time, we cannot rule out the possibility that
phenylsulfate might be taken up by the Zymbal gland
(from surrounding blood supply); once in this organ,
phenylsulfate couldbe rapidlyhydrolyzedby sulfatase to
yield phenol, which in turn, could be further oxidized
and/or glucuronidated. The metabolic capacity of the
Zymbalgland inregard todeconjugatingorhydrolyticac-
tivities has notbeenwell characterized (29,32). Relatively
little is known on the distribution of sulfatases in the
Zymbal gland(33). However, it is interesting to speculate
thatthe presence ofsulfatasesinthe Zymbal glandmight
provide amechanismbywhich sulfate conjugates ofphe-
nolicbenzene metabolites canbe hydrolyzed to yieldfree
phenolic metabolites, capable of undergoing further ac-
tivation or inactivation processes. Work is underway to
investigate this possibility.
Since the Zymbalgland is a specialized sebaceousgland
in rodents (34), it is reasonable to expect that lipophilic
chemicals like benzene would partition readily into the
gland. However, results ofthese studies showed that ac-
cumulation ofbenzene does not occurin the Zymbalgland
following single or multiple oral doses but that Zymbal
glandmetabolismproduces aprofile ofmetabolites, which
is somewhat different from that ofother organs and tis-
sues examined. Perhaps this differential metabolism
might contribute to the carcinogenic activity ofbenzene
in the Zymbalgland and other target tissues. Continued
metabolism andpharmacokinetic studies after single and
repeated oral doses of benzene may provide further in-
formation for determining the likely reactive species and
pathways involved in causing the formation of solid
tumors in the rat.
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